Aplicación asistencial de la Next Generation Sequencing en la caracterización morfomolecular del carcinoma de pulmón. Estudio de 170 casos.

Natalia Rodon1, Montse Verdú1,2, Olga Diaz1, Yessica No1 y Xavier Puig1,2,3.

1BIOPAT. Biopatologia Molecular, SL, Grup Assistència, Barcelona; 2Histopat Laboratoris, Barcelona; 3Hospital de Barcelona, SCIAS, Grup Assistència, Barcelona.

INTRODUCCIÓN

La caracterización molecular de los carcinomas de pulmón es esencial para la selección del tratamiento dirigido más adecuado para cada paciente y puede aportar información pronóstica de gran utilidad. La incorporación de la Next Generation Sequencing (NGS) como metodología de diagnóstico estándar en nuestro laboratorio supuso un cambio de paradigma en el abordaje de […]

2018-06-23T12:22:22+00:00

Detection of ALK and ROS1 rearrangements using Next Generation Sequencing in lung cancer patients: comparison between FISH, IHC and NGS

Sergi Clavé1,2, Natalia Rodon3, Lara Pijuan1, Alba Dalmases1,2, Olga Díaz3, Álvaro Taus4, Marta Lorenzo1,2, Pedro Rocha4, Ana M. Muñoz-Mármol5, Glòria Oliveras6, Joaquim Bosch6, Blanca Espinet1,2, Beatriz Bellosillo1,2, Xavier Puig3, Edurne Arriola2,4, Marta Salido1,2.

1 Servei de Patologia, Hospital del Mar, Barcelona. 2 Programa de Recerca en Càncer, Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona. 3 BIOPAT. Biopatologia Molecular SL, Grup Assistència, Barcelona. 4 Servei d’Oncologia, Hospital del Mar, Barcelona. 5 Servei d’Anatomia Patològica, Hospital Germans Trias i Pujol, Badalona. 6 Departament […]

2018-06-23T12:26:41+00:00

EGFR mutations in lung cancer. A morphological, immunohistochemical and molecular study of lung adenocarcinoma

Verdú Ma,b,∗, Trias Ia,b,c, Román Rb, Rodón Nb, Pubill Ca, Calvo Md, Garcia-Pelaez Bb, Diaz Ob, Puig Xa,b,c

a Histopat Laboratoris, Barcelona, Spain, b BIOPAT Biopatologia Molecular, Grup Assistencia, Barcelona, Spain, c Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain, d Universitat de Barcelona (UB), Departament d’Estadística, Barcelona, Spain

 

Abstract

The study of epidermal growth factor receptor mutations has become essential for the treatment of lung cancer. The aim of this study was to find a correlation between morphological changes and EGFR mutational […]

2016-06-22T11:29:12+00:00

Cross-reactivity of EGFR mutation-specific immunohistochemistry assay in HER2 positive tumors

Verdu M1,2, Trias I1,2,3, Roman R1, Rodon N1, Pubill C2, Arraiza N2, Martinez B2, Garcia-Pelaez B1, Serrano T1,2,3, Puig X1,2,3.

1BIOPAT, Biopatologia Molecular SL, Grup Assistència, Barcelona, Spain. 2Histopat Laboratoris, Barcelona, Spain. 3Hospital de Barcelona-SCIAS, Grup Assistència, Barcelona. Spain.

Abstract

The co-expression of HER2 and EGFR L858R in a solitary nodule removed from the lung, whose mutation was not confirmed by molecular techniques, made us think about the possible existence of a cross-reaction between HER2 and the EGFR L858R-specific antibody. Our study was […]

2014-11-24T12:17:42+00:00

EGFR L858R Antibody Cross-Reaction in HER2 Positive Breast and Gastric Carcinomas

Montse Verdu1,2, Natalia Rodon2, Ruth Roman2, Isabel Trias1,2,3, Carme Pubill1, Nuria Arraiza1, Begonya Martinez1, Beatriz Garcia-Pelaez2 and Xavier Puig1,2,3.

1Histopat laboratoris, Barcelona, Spain; 2BIOPAT. Biopatolodia Molecular, Grup Assistencia, Barcelona, Spain and 3Hospital de Barcelona, SCIAS, Grup Assistencia, Barcelona, Spain.

 

Background: The use of epidermal growth factor receptor (EGFR) mutation-specific antibodies is likely to get soon incorporated into clinical practice due to its proven correlation with the presence of EGFR mutation in lung adenocarcinoma, especially in cases with limited tumor material, or in […]

2014-03-13T12:45:51+00:00